Feature | Radiation Therapy | October 21, 2016 | Dave Fornell

Company has continued to produce, sell and service non-FDA cleared devices for radiation therapy

Multidata Systems International Corp, water phantom, FDA warning

October 21, 2016 — The U.S. Food and Drug Administration (FDA) issued a letter calling on radiation oncologists, medical physicists, dosimetrists and radiation therapists to stop using all medical devices manufactured and sold by Multidata Systems International Corp. The FDA said it is concerned about the risks to patients from the use of devices, which never received FDA market clearance. 

William Maisel, M.D., MPH, deputy for the Center Director for Science, Center for Devices and Radiological Health, FDA, said the agency knows of at least two Multidata medical devices that the company manufactured and distributed in the United States for which FDA never received nor reviewed 510(k) premarket notifications. These devices include: (1) accessories to radiation therapy devices including the Real Time Dosimetry (RTD) Waterphantom System; and (2) the Dual Channel Electrometer. In addition, Multidata has not registered or listed their devices with the FDA, as required by federal law.

Since 2003, Multidata has been under a Consent Decree of Permanent Injunction entered by the U.S. District Court for the Eastern District of Missouri (civil action no. 4:03cv575). Maisel said the decree prohibits Multidata from designing, manufacturing, processing, and distributing medical devices, among other restrictions. The FDA has learned, however, that Multidata manufactured and distributed medical devices in violation of the decree, including repairing and exchanging waterphantom devices for newer design models.

“The FDA is concerned that healthcare providers may be unaware of the risks associated with these devices and urges facilities to discontinue the use of any devices manufactured by Multidata,” Maisel said. He explained these need to be dispose of appropriately and replaced with accessories to radiation therapy devices and radiation treatment planning software that have been reviewed and cleared by FDA.

Analysis of the Problem

At this time, it is not known how many devices manufactured by Multidata are currently in use in hospitals and clinics throughout the United States. The FDA is not aware of adverse event reports associated with the use of Multidata's devices since Multidata has been under the decree, but because the FDA has not received or reviewed 510(k) premarket notifications, the agency is concerned about the potential risk to patients from the devices.

FDA Recommendations

In a letter to providers, Maisel urged discontinuing the use of any devices manufactured by Multidata and disposal of them appropriately. The FDA urges use of accessories to radiation therapy devices and radiation treatment planning software that have been cleared by the FDA. Registered manufacturers of these types of devices are listed under the IYE product code in the FDA’s Registration and Listing Database (www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm).

Maisel also said centers should follow quality assurance procedures to verify treatment plans by independent means, which may include manual calculations or measurements of radiation doses.

FDA Actions

Through inspections, the FDA learned that Multidata was designing, manufacturing, processing and distributing medical devices in violation of the decree. As a result, on March 3, 2016, the FDA sent a letter to Multidata ordering the firm to cease designing, manufacturing, processing, packing, repacking, labeling, installing, holding for sale and distributing any medical device. The company has now permanently ceased operations and will be dissolving.

The FDA will keep the public informed if significant new information becomes available, Maisel said. 


Related Content

News | Proton Therapy

Sept. 28, 2026 — Penn Medicine and Ion Beam Applications (IBA) have formed Noventra Oncology Alliance, a new joint ...

Time September 28, 2026
arrow
News | ASTRO

Sept. 22, 2026 — Leading experts in radiation therapy from the Abramson Cancer Center (ACC) of the University of ...

Time September 24, 2026
arrow
News | ASTRO

Sept.16, 2026 — For appropriately selected patients with muscle-invasive bladder cancer, preserving the bladder can be a ...

Time September 17, 2026
arrow
News | Radiology Imaging

Sept. 1, 2026 — Leo Cancer Care and GE HealthCare have announced that the two companies intend to work together on GE ...

Time September 11, 2026
arrow
News | ASTRO

Sept. 9, 2026 — The 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, will take place Sept. 26 to 30 ...

Time September 11, 2026
arrow
News | Radiation Oncology

Sept. 2, 2026 — Children with one of the deadliest forms of brain cancer may benefit from an additional course of ...

Time September 03, 2026
arrow
News | Radiation Therapy

Aug. 13, 2026 — An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence ...

Time August 17, 2026
arrow
News | Prostate Cancer

Aug. 13, 2026 — Artera has announced the enrollment of the first patient in its DIRECT-AI registry study, marking the ...

Time August 14, 2026
arrow
News | Innovative Hospitals

July 27, 2026 — Vanderbilt Health and Siemens Healthineers have entered into a multi-year, $87 million Value ...

Time July 28, 2026
arrow
News | ASTRO

July 22, 2026 — The American Society for Radiation Oncology (ASTRO) has announced the 39 members who will receive the ...

Time July 23, 2026
arrow
Subscribe Now